Resveratrol as a BCL6 natural inhibitor suppresses germinal center derived Non-Hodgkin lymphoma cells growth
Open Access
- 15 January 2025
- journal article
- research article
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 79 (2) , 399-411
Abstract
Non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and follicular lymphoma (FL), predominantly arise from B cells undergoing germinal center (GC) reactions. The transcriptional repressor B-cell lymphoma 6 (BCL6) is indispensable for GC formation and contributes to lymphomagenesis via its BTB domain-mediated suppression of target genes. Dysregulation of BCL6 underpins the pathogenesis of GC-derived NHL. While pharmacological targeting the BCL6-BTB domain has shown therapeutic promise, natural product-based inhibitors remain underexplored. In this study, resveratrol, a polyphenolic compound derived from grapes, was identified as a potent BCL6 inhibitor through a comprehensive screen of traditional Chinese medicine monomers using Homogeneous Time-Resolved Fluorescence (HTRF) assay. As a BCL6 natural inhibitor, resveratrol effectively disrupted the BCL6/SMRT interaction, reactivated suppressed gene expression, and inhibited the proliferation of GC-derived NHL cells. It also exhibited synergistic efficacy when combined with EZH2 and PRMT5 inhibitors. In vivo, resveratrol suppressed GC formation, reduced follicular helper T-cell frequencies, impaired class-switch recombination, and disrupted immunoglobulin affinity maturation. Furthermore, it markedly inhibited the progression of GC-derived NHL in animal models. Our findings demonstrate that resveratrol functions as a natural BCL6 inhibitor with significant therapeutic potential for the treatment of GC-derived NHL. Graphical abstractKeywords
Funding Information
- Chongqing Postdoctoral Science Foundation (cstc2021jcyj-bshX0034, cstc2021jcyj-bshX0009, cstc2021jcyj-bshX0188)
This publication has 53 references indexed in Scilit:
- The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesisPathologie Biologie, 2007
- Comparative Studies of the Antioxidant Effects of Cis- and Trans- ResveratrolCurrent Medicinal Chemistry, 2006
- Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in miceCancer Cell, 2005
- The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cellsNature, 2004
- Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cellsNature Medicine, 2004
- Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma.2004
- Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression ProgramImmunity, 2002
- The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRTOncogene, 1998
- The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammationNature Genetics, 1997
- Alterations of a Zinc Finger-Encoding Gene, BCL-6 , in Diffuse Large-Cell LymphomaScience, 1993